CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7001 result(s)

Non-Pharmacological Interventions for Chronic Non-Cancer Pain: Physical Activity

Event Date: September 23, 2020
Result type: Events

Because of the prevalence and burden of chronic pain, health care providers are in search of the best multifaceted approach for treatment knowing that relying on opioids alone can be ineffective and carries substantial risks. Join CADTH for a webinar on the current evidence on physical activity for chronic, non-cancer pain. The target audience f...

siponimod (Mayzent)

Last Updated: September 17, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: siponimod
Indications: Secondary progressive multiple sclerosis

  • Brand Name: Mayzent
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0631-000
  • Project Status: Complete
  • Submission Type: New

cabotegravir/rilpivirine (Vocabria and Cabenuva)

Last Updated: September 17, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: cabotegravir sodium cabotegravir-rilpivirine
Indications: HIV-1 infection

  • Brand Name: Vocabria and Cabenuva
  • Manufacturer: ViiV Healthcare ULC
  • Project Number: SR0628-000
  • Project Status: Complete
  • Submission Type: New

CADTH Weekly COVID-19 Update

Last Updated: September 21, 2020
Result type: Reports
Product Line: New at CADTH

CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time. Our COVID-19 evidence portal contains the latest COVID-19 information from CADTH and other respected organizations. Content is updated daily to reflect the rapidly changing and growing state of the international scientific evidence...

Non-Opioid Options for Managing Pain

Last Updated: September 21, 2020
Result type: Tools

Canada is in the midst of an opioid crisis. And even with growing awareness of the risks, opioids continue to be used extensively in the management of pain. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain recommends optimizing non-opioid pharmacotherapy and non-pharmacological therapy rather than a trial of opioids for patien...

erenumab (Aimovig)

Last Updated: September 18, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: erenumab
Indications: Migraine

  • Brand Name: Aimovig
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0578-000
  • Project Status: Complete
  • Submission Type: New